Medical Watch Disease & Treatment News

Breakthrough for MPS-II kids: FDA grants accelerated approval to new drug for rare childhood dementia.

• Strikes around age 2, causing body-wide...

Phase 3 breakthrough: Daraxonrasib extended median survival to 13.2 months vs 6.7 months on chemo for pretreated metastatic pancreatic cancer.
-...

Boost vitamin D now for potential long-term brain protection: New study links higher midlife levels to lower tau tangles 16 years later.

Key findings...

Don't miss the Alzheimer's Association's free virtual event today:

• New advancements in treatments that slow disease progression
• Details on...

Emerging strategies tackle pancreatic cancer's resistance head-on:

• Immunotherapy breakthrough: Agonistic CD40 reprograms suppressive Tregs into...

Potential game-changer for Parkinson's: Biogen/Ionis' BIIB094 antisense drug achieved 59% LRRK2 reduction and 50% pRab10 drop in CSF, proving CNS...

Trend alert: AI-driven drug discovery and gene therapy are accelerating AMR solutions.

• AI evolution: From predictive to generative models,...

Intercoastal Memory Clinic's second annual event fills auditorium with patients and caregivers seeking community resources.

• Pioneering infusions...

NIH-funded UT Austin breakthrough reveals tiny Al3Cas12f enzyme that fits AAV vectors for in vivo delivery, overcoming size limits of larger CRISPR...

Breakthrough for DMD treatment: FDA grants IND clearance for Mesoblast to proceed straight to registrational trial of Ryoncil® (remestemcel-L), first...

Ethical breakthrough ends embryo debates: Yamanaka's 2006 discovery reprograms adult cells into pluripotent iPSCs without destroying embryos.
-...

Critical funding milestone for neurodegenerative therapy:

• $10M public offering plus $1.5M from Chair extends cash to Q2 2027
• Funds Phase 3 AD...

Breakthrough funding propels pegtarazimod, a first-in-class peptide, through Phase II for Hypoxic Ischemic Encephalopathy (HIE) – a devastating...

Pivotal progress in essential tremor treatment:

• Essential3: First positive Phase 3 program for ulixacaltamide, addressing a disorder affecting ~7M...

Key highlights from Lundbeck's announcements:

• Neurology portfolio data presented at American Academy of Neurology (AAN) Annual Meeting
• Parkinson's...

Promising Phase 2 results for BioNTech/DualityBio's HER2-targeted ADC in heavily pre-treated patients:

• Confirmed ORR 47.9% (centrally tested, n=96)...

Simple prevention insight: Higher vitamin D in midlife predicts fewer tau tangles later, a hallmark of Alzheimer’s.

• Study evidence: In 793 adults,...

Key genetic insights from a 28,000-person study pave the path to DNA-tailored obesity/diabetes treatments:

• GLP1R variant adds ~0.7kg extra weight...

Game-changing blood markers for GBM:

• Activated CD8+ NKT cells and Delta-24 antiviral antibodies correlate with long-term survival after oncolytic...

Alzheimer’s Therapy Advances

• 🔥 FDA-Approved Disease-Modifying Antibodies: Lecanemab (Leqembi) and donanemab (Kisunla) are the first monoclonal...